Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Voice Acoustics in Healthy Adults (taVNS-VOICE)

9 ноября 2026 г. обновлено: SEFA HAKTAN HATIK, Sinop University

Acute Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Acoustic Voice Parameters and Autonomic Function in Healthy Adults: A Randomized, Sham-Controlled, Three-Period Crossover Trial

This study aims to investigate the immediate effects of transcutaneous auricular vagus nerve stimulation (taVNS) on voice characteristics and autonomic function in healthy adults.

A total of 36 healthy adults aged 18-30 years will participate in this randomized, sham-controlled, three-period crossover trial. Each participant will receive three interventions in a randomized order: unilateral active taVNS, bilateral active taVNS, and sham stimulation. Each intervention will last 20 minutes, with at least seven days between visits.

Voice characteristics will be evaluated before and after each intervention using acoustic analysis. The primary outcome will be shimmer, a measure of variation in voice amplitude. Secondary outcomes will include jitter, harmonics-to-noise ratio, and fundamental frequency. Perceived vocal effort, heart rate, and pulse rate variability will also be assessed.

The study will compare the immediate effects of unilateral, bilateral, and sham stimulation on voice stability and explore possible relationships between voice changes and autonomic responses.

Обзор исследования

Статус

Еще не набирают

Условия

Вмешательство/лечение

Подробное описание

This prospective, randomized, sham-controlled, three-period crossover trial will investigate the acute effects of unilateral and bilateral transcutaneous auricular vagus nerve stimulation (taVNS) on acoustic voice parameters and autonomic function in healthy adults.

Thirty-six participants aged 18-30 years will be allocated to one of six intervention sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Each participant will complete three intervention visits separated by a washout period of at least seven days.

The intervention conditions will include: (A) unilateral active stimulation of the left cymba conchae, (B) bilateral active stimulation of the cymba conchae, and (C) bilateral sham stimulation applied to the earlobes with an initial brief sensory stimulation followed by gradual reduction of current to zero. Stimulation will be delivered using Nurosym devices at 20 Hz and 200 μs for 20 minutes. Active stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Acoustic voice assessment will involve three recordings of sustained /a/ phonation before and after each intervention. Recordings will be analyzed using Praat software. Shimmer (%) will be the primary outcome, while jitter (%), harmonics-to-noise ratio (dB), and fundamental frequency (Hz) will be secondary outcomes.

Perceived vocal effort will be assessed using a 100-mm visual analogue scale. Autonomic responses will be evaluated using pulse rate variability measurements obtained with the Polar Verity Sense device, including RMSSD, SDNN, and mean heart rate.

Primary analyses will use linear mixed-effects models to compare changes across intervention conditions while accounting for repeated measurements and study periods. Adverse events and stimulation tolerability will be monitored throughout the study.

Тип исследования

Интервенционный

Регистрация (Оцененный)

36

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Sefa Haktan Hatık Principal Investigator, PhD, MSc, Physiotherapist
  • Номер телефона: +90 505 876 1553
  • Электронная почта: haktanhtk@gmail.com

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 30 лет (Взрослый)

Принимает здоровых добровольцев

Да

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Adults aged 18-30 years.
  • Self-reported good general health without known systemic diseases preventing safe participation.
  • Native Turkish speakers.
  • No current hoarseness, vocal strain, or known laryngeal/voice disorders.
  • No current use of cigarettes, electronic cigarettes, heated tobacco, or other nicotine products.
  • Ability and willingness to attend three intervention visits separated by at least 7 days.
  • Ability to understand and follow study procedures.
  • Provision of written informed consent.

Exclusion Criteria:

  • Known cardiovascular disease, clinically significant arrhythmia, uncontrolled hypertension or hypotension, or unexplained syncope.
  • History of epilepsy, seizures, or serious neurological disorders.
  • Known vocal fold or laryngeal pathology, chronic voice disorders, previous laryngeal surgery, or significant hoarseness.
  • Active respiratory infection, laryngitis, sore throat, or febrile illness.
  • Ear infections, wounds, dermatological lesions, hypersensitivity, or piercings interfering with electrode placement.
  • Pacemakers, implantable cardioverter-defibrillators, or other active electronic implants.
  • Pregnancy or suspected pregnancy.
  • Current tobacco or nicotine use.
  • Regular use of medications significantly affecting autonomic function or voice, including beta-blockers, antiarrhythmics, anticholinergics, sedatives, or psychoactive medications.
  • Failure to comply with pre-assessment restrictions concerning caffeine, alcohol, vigorous exercise, or vocal loading; visits may be rescheduled when possible.
  • Clinically significant intolerance or adverse reactions to stimulation requiring discontinuation.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Фундаментальная наука
  • Распределение: Рандомизированный
  • Интервенционная модель: Назначение кроссовера
  • Маскировка: Одинокий

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Sequence ABC

Unilateral active taVNS, followed by bilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Экспериментальный: Sequence ACB

Unilateral active taVNS, followed by bilateral sham stimulation, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Экспериментальный: Sequence BAC

Bilateral active taVNS, followed by unilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Экспериментальный: Sequence BCA

Bilateral active taVNS, followed by bilateral sham stimulation, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Экспериментальный: Sequence CAB

Bilateral sham stimulation, followed by unilateral active taVNS, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Экспериментальный: Sequence CBA

Bilateral sham stimulation, followed by bilateral active taVNS, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change in Shimmer (%)
Временное ограничение: At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.

Shimmer (%) will be measured using Praat software from three sustained /a/ phonations. The stable middle 3-second segment of each recording will be analyzed, and the mean of three measurements will be used. Change will be calculated as post-intervention minus baseline shimmer.

At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.
Change in Jitter (%)
Временное ограничение: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in cycle-to-cycle fundamental frequency variation, measured using Praat software from three sustained /a/ phonations.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Harmonics-to-Noise Ratio (dB)
Временное ограничение: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in voice harmonic-to-noise ratio, measured using Praat software from three sustained /a/ phonations.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Fundamental Frequency (Hz)
Временное ограничение: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in mean fundamental frequency (F0), measured using Praat software from three sustained /a/ phonations.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Perceived Vocal Effort (mm)
Временное ограничение: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in perceived vocal effort assessed using a 100-mm visual analogue scale (VAS), where higher scores indicate greater perceived vocal effort.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in RMSSD (ms)
Временное ограничение: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Change in the root mean square of successive differences (RMSSD), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
Change in SDNN (ms)
Временное ограничение: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Change in the standard deviation of normal-to-normal pulse intervals (SDNN), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
hange in Mean Heart Rate (bpm)
Временное ограничение: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Change in mean heart rate measured using Polar Verity Sense during 5-minute recordings.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
Change in LF/HF Ratio
Временное ограничение: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Exploratory analysis of the low-frequency to high-frequency power ratio derived from pulse rate variability recordings.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Оцененный)

16 ноября 2026 г.

Первичное завершение (Оцененный)

15 января 2027 г.

Завершение исследования (Оцененный)

31 января 2027 г.

Даты регистрации исследования

Первый отправленный

9 ноября 2026 г.

Впервые представлено, что соответствует критериям контроля качества

9 ноября 2026 г.

Первый опубликованный (Действительный)

16 ноября 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

16 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

9 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • TAVNS-VOICE-CO-2026-01

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Описание плана IPD

Individual participant data will not be shared with external researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form in scientific publications.

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .